Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Expanded Access Guidances Fail To Achieve Détente With Advocates

Executive Summary

The number of requests to use investigational drugs outside of clinical trials has grown and FDA typically approves all requests, but advocates still insist the process is set up to fail patients.

You may also be interested in...

FDA Can't Win On Guidances: Expanded Access Policy, Duchenne Worries Collide

Keeping guidances in draft form makes Congress angry, but finalizing them gives Wall Street the vapors.

Expanded Access INDs: FDA’s Near-Perfect Approval Rate Underscores Problems, Advocates Say

CDER continues to allow most submissions it receives for access to investigational drugs but critics say barriers prevent vast numbers of patients from requesting access.

FDA “Breakthrough” Designation Bill Revives Debate About Legislating Flexibility

FDA appears to support the idea behind the bipartisan bill, which would allow the agency to meet with the sponsor early in the development process when a candidate shows substantial improvement over existing therapies and consider expedited trials going forward.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts